Allkem (Australia, GEMS Constituent): Merger with Livent (USA, Small Cap) – Preliminary Notice

Wilshire notes the upcoming merger between Allkem (Australia, GEMS Constituent) and Livent (USA, Small Cap) to form Arcadium Lithium plc.

In the transaction, Allkem shareholders will receive one CHESS Depositary Interest of Arcadium Lithium listed on ASX, or, upon election, one share of Arcadium Lithium, to be listed on NYSE. Livent shareholders will receive 2.406 shares of NYSE-Listed Arcadium Lithium for every share held. The last day of trading of Allkem on ASX is expected to occur on December 21, 2023. The first day of trading on NYSE for Arcadium Lithium is expected to occur January 4, 2024.

Wilshire has confirmed that the combined company Arcadium Lithium should be deemed a US company for nationality purposes and Arcadium Lithium will have a size reflective of the Small Cap segment within the FT Wilshire 5000 Index Series.

Based on the current disclosed timetable, and in order to reflect the market and minimize client turnover, Wilshire anticipates the following treatment:

**December 21, 2023 (at the close):**

Wilshire will remove Allkem from all indexes and upweight Livent within its current indexes at the terms of 2.406 shares of Allkem for every share of Livent.

**January 3, 2024 (at the close):**

Wilshire will process a 2.406:1 stock split on Livent, and process name and identifier changes to reflect holdings in the new company, Arcadium Lithium. Arcadium Lithium will retain Allkem’s current memberships within the FT Wilshire 5000 Index Series.

Wilshire will release a further notice upon event finalization.

If you have any questions or comments, please contact us at index.support@wilshire.com.